Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon investor briefing presentation 30 April 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the following presentation, which will be presented by Interim Executive Chairman, Mr Sergio Duchini at in-person investor briefing events being held in Sydney today and Perth on Monday, 4 May 2026. The presentation highlights recent corporate, clinical and operational progress, as well as upcoming value-defining milestones for NUZ-001. The formal presentation will be followed by an interactive Q&A session and the opportunity to network with members of the management team. The Sydney and Perth briefings form part of a national investor engagement series, with additional capital city locations to be announced shortly. Event details: Sydney Perth Date Thursday, 30 April, 2026 Date Monday, 4 May, 2026 Time 5:00 – 7:00pm AEST Time 5:00 – 7:00pm AWST Location Morgans Aurora Place, Level 21/88 Phillip St, Sydney Location Morgans Level 4, 50 Colin St West Perth RSVP To irpr@irdepartment.com.au – please note in your email that you would like to attend the Neurizon Sydney investor briefing event. RSVP To irpr@irdepartment.com.au – please note in your email that you would like to attend the Neurizon Perth investor briefing event. The presentation slides are attached to this announcement. -ENDS- This announcement has been authorised for release by Sergio Duchini, Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited. For any questions, comments, or further information regarding Neurizon, please email enquiries@neurizon.com, or contact: Marketing & Corporate Affairs Lidija Damjanovic Marketing & Corporate Affairs Email: lidija@neurizon.com Phone: +61 (0) 425 700 504 Investor Relations Henry Jordan Six Degrees Investor Relations Email: henry.jordan@sdir.com.au Phone: +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited ABN 35 094 006 023 Company Presentation April 2026 Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company. Company Presentation April 2026 2 Future Matters This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. US Disclosure This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers. To lead the development of neurodegenerative treatments towards a promising new horizon for patients. Our Vision Accelerating Patient Access to Innovative ALS Treatment Our Promise Driving Clinical Progress Unlocking the potential of Neurizon to address high unmet need in neurodegenerative diseases Delivering commercial readiness and stakeholder value Corporate Overview 5 Current Share Price (NUZ/NUZOA) $0.085/ $0.002 52 Week Low / High (NUZ) $0.078/ $0.175 No. of Shares (NUZ) 742,091,181 Listed Options (NUZOA) 116,315,955 Unlisted Options1 23,519,011 Convertible Notes2 3,575,500 Market Capitalisation $63.1m Cash (as at 31-Mar-26) $16.7m Convertible Note Debt3 ($5.6m) Net Cash $11.1m Enterprise Value $51.8m Enterprise Value (fully diluted) $63.8m Capital Structure (AUD$) 29 April 2026 Share Price Performance Board & Management Mr Chek Loon Tan 5.73% Graham & Lynne Darcy Group 3.00% Elanco Tiergesundheit AG 2.53% Mr GJ & Mrs G Van Blommestein 2.21% Board & Management 4.25% Top Shareholders (at 29 April 2026) Mid-stage biotechnology company targeting human neurodegenerative diseases Mr Sergio Duchini Executive Chairman Dr Michael Thurn Non-Executive Director Mr Marcus Hughes Non-Executive Director Dr Katie MacFarlane Non-Executive Director Mr Dan O’Connell Chief Financial Officer Mr Stefan Ross Company Secretary Closing Price (AUD$) Volume (m) 1 5,000,000 options with exercise price A$0.3325, expiry Jun 2026 and 18,135,011 options with exercise price A$0.20, expiry 30 Jun 2032. 2 Convertible note issued to Obsidian Global GP, LLC. Refer ASX: NUZ – Cleansing Statement – Section 708A(12C)(e) & ASX: NUZ - Drawdown of tranche one of strategic financing facility (both releasedon 27 February 2026) 3 Debt reflects convertible notes issued to Obsidian Global GP, LLC with a face value of US$1.11 translatedto AUD at 0.705. Company Presentation April 2026 - 1 2 3 4 5 6 0.00 0.10 0.20 0.30 0.40 0.50 29-Apr-25 29-Jun-25 29-Aug-25 29-Oct-25 29-Dec-25 28-Feb-26 Volume SP 6 Company Presentation April 2026 Building Momentum Across Key Growth Phases THEN NOW NEXT Foundation and preparation Active clinical execution Data generation and expansion We have built the foundation, brand and pipeline. Validated target and mechanism Established clinical and regulatory path HEALEY trial participation confirmed Strengthened team and partnerships Executing our clinical programs with focus, discipline and capital-efficient execution. Advancing NUZ-001 through Phase2/3 HEALEY ALS Platform Trial Driving key catalyst milestones Expanding partnerships and commercial opportunities Delivering data. Creating value. Expanding impact. Key clinical readouts and regulatory progress Potential partnering and licensing transactions Pipeline expansion into other neurodegenerative diseases Delivering long-term value for shareholders NUZ-001: Potential application to range of neurodegenerative diseases 7 TDP-43 ALS/AD/PD/FTD/CTE Amyloid beta AD/PD Tau AD/PD/FTD/CTE/PSP alpha Synuclein AD/PD NUZ-001 is a mechanism-driven, disease-agnostic approach to treating neurodegeneration by rebalancing proteostasis and addressing core cellular dysfunction. AD = Alzheimer’s Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson’s Disease; PSP = Progressive Supranuclear Palsy ALS is a current priority, but NUZ-001 has potential application to a range of neurodegenerative diseases. mHTT HD Company Presentation April 2026 New preclinical data show NUZ-001 increases activity of multiple protein clearance pathways in neuronal models: autophagy and proteasomal systems. Phase 1 Access to manufacturing at scale critical to future commercialisation Access to animal safety data and manufacturing data critical to support future trials and potential regulatory approvals Strongly Positioned with Regulatory and Commercialisation Requirements for Realisation Derisked regulatory approval process Drug / Dosage Form NUZ-001 Oral Tablets NUZ-001 Oral Tablets or Liquid Partnerships & Licensing HEALEY ALS Platform Trial Elanco Licensing Agreement Preclinical & research partners Amyotrophic Lateral Sclerosis (Motor Neurone Disease) Neurodegenerative Diseases • Identify Next Target Indication • Preclinical Data • Elanco Supply Agreement • 50% Enrolment • 100% Enrolment Complete HEALEY ALS Platform Trial Indication Preclinical Phase 2 Phase 3 Approved/ Marketed Next Major Catalysts Potential for accelerated approval based on Phase 2 data, supported by Elanco licensing agreement Registrational adaptive Phase 2/3 clinical study 8 HEALEY Trial: Opportunity for accelerated approval Initial focus is ALS, a rare disease with high unmet need and the possibility of accelerated approval on Phase 2/3 data. Potential for broader application being developed through pre-clinical program. Company Presentation April 2026 Expanding Relationship with Elanco The License Agreement was a foundational step that formalized Neurizon's relationship with Elanco and which supports future regulatory approval and commercialisation. This agreement is an exclusive global licensing agreement that provides worldwide rights to utilise Elanco's intellectual property for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Elanco is now a top five shareholder in Neurizon and has appointed an experienced business development executive as a Board Observer. Through its participation in the December 2025 share placement, Elanco is a top five shareholder in Neurizon. It has also appointed Justine Conway (Global Head of Business Development) as a Board Observer. Supply Agreement execution expected in Q2 CY2026 Finalisation of this important agreement remains a priority for both Neurizon and Elanco. It is expected to be executed in Q2 CY2026. This agreement will provide access to a long-term, scalable GMP-compliant monepantel - the active pharmaceutical ingredient in NUZ-001. Both companies are constructively working on finalising contractual terms to support Neurizon’s commercial supply requirements. A recent shipment of monepantel has secured required supply to the end of the HEALEY ALS Platform trial. License Agreement Strategic Investment Supply Agreement 9 Relationship with Elanco continues to expand with execution of the Supply Agreement expected in Q2 CY2026 Company Presentation April 2026 10 ‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones Enrollment Complete Q3-Q4 2026 First Patient Dosed 160 patients enrolled in the trial First patient screened for eligibility Last Patient Dosed Q1 2026 First Patient Screened Q2-Q3 2027 Last participant receives final dose Database Lock Q3 2027 Clinical trial database locked for analysis Topline Data Released Topline results of the trial announced Q3 2027 First participant dosed in Regimen I Platform Trial IND submitted to regulatory authorities Q4 2025 IND Amendment Submission NUZ-001 entry accepted Q4 2025 FDA Clearance Q1 2026 5 6 7 8 Anticipated Trial Execution Updates Site Activation Confirmation of additional clinical sites opened and recruitment underway Enrolment Milestones Achieved Progress updates on patient recruitment (e.g., 50% enrolled, enrolment complete) Completion Milestones Last Patient In (LPI) and Last Patient Last Visit (LPLV), with timing guidance for topline data release Company Presentation April 2026 HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 11 Inclusion/Exclusion Criteria 36-week Double Blind Placebo Controlled Period 36-week Active Treatment Extension Period 3:1 Randomisation n=160 participants Primary Endpoint • Change from baseline through Week 36 in disease severity, measured by the ALSFRS-R total score and survival Secondary Endpoints • Change from baseline through Week 36 in secondary efficacy measures (e.g., respiratory function via slow vital capacity (SVC)) • Survival through Week 36 (death or equivalent endpoint) NUZ-001 10 mg/kg Placebo NUZ-001 10 mg/kg Company Presentation April 2026 Regimen “I” Participant Enrollment Update 57 50 106 36 12 Activated Sites Master Screening Dosed Participants Regimen Assignment Company Presentation April 2026 Numbers referred to above are as of 28 April 2026. Placement & Entitlement Offer • Raised ~A$7.1 million under the Placement, through issue of New Shares at A$0.08 per New Share for the HEALEY ALS Platform Trial • 2-for-5 Entitlement Offer at A$0.08 per New Share, which raised a total of A$8.5 million through the entitlement offer (January 2026) and the shortfall placement (April 2026). Research & Development (R&D) Tax Rebate • Neurizon’s Advance and Overseas Finding (AOF) provides a cash rebate for foreign R&D spend • Cash rebate of at least 43.5% on HEALEY spend • AOF is binding on Australian Tax Office and AusIndustry - providing an important, non- dilutive source of funds Convertible Note Facility • Convertible Note Facility for up to A$20 million with Obsidian Global GP, LLC • Initial draw of A$5 million completed in February 2026 • Committed facility - option but no obligation to use remaining A$15 million in the facility • Includes trading restrictions to protect shareholder and optionholder interests Neurizon’s funding strategy has been developed with a focus on protecting shareholders’ interests through flexible funding instruments and minimising dilution. This includes the ability to finance the company’s R&D rebate receivables and the ability to displace the convertible note facility, if appropriate to do so. 13 HEALEY: Funding secured Strong shareholder support has secured adequate funding for HEALEY ALS Platform trial1 1 See ASX: NUZ - Equity Raising Presentation (23 December 2025), including details of funding strategy and identified risks. Company Presentation April 2026 14 ALS: High Unmet Need with Significant Value Potential A serious, rapidly progressive disease with limited treatment options. Meaningful innovation in ALS can create value for people living with ALS and the market. ~30,000+ people living with ALS in the U.S only.1 Rapid progression Median survival often 2–5 years from diagnosis² High unmet need Limited treatment options. Need remains for therapies addressing underlying disease biology. Aims to inhibit TDP- 43 aggregation and restore proteostasis (NUZ-001 mechanism of action). Addresses key ALS pathology Entered Phase 2/3 HEALEY ALS Platform Trial. Clinical- stage program Exploring relevance in other neurodegenerative diseases with shared pathology. Multi- Indication potential Convenient, scalable formulation with the potential for broad patient access. Oral administration NUZ-001 Investigational oral therapy Designed to address key disease biology in 97% of people living with ALS WHY NUZ-001 IS RELEVANT THE NEED IN ALS COMMERCIAL VALUE POTENTIAL ALS market has demonstrated significant strategic value Multiple large-value transactions and licensing deals in recent years. Strong interest in differentiated therapies, particularly with oral or disease-modifying potential. Appeared safe and generally well-tolerated with signals of efficacy in exploratory studies 1. The ALS Association; www.als.org; accessed April 2026 2. Chio A, et al Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6);310-323 Potential value drivers for Neurizon Regulatory milestones Partnership and licensing optionality Pipeline expansion into HD and other neurodegenerative diseases Company Presentation April 2026 ALS: High Unmet Need with Significant Value Potential Company Presentation April 2026 15 Multiple large-value transactions and deals in recent years Key ALS Value Reference Point: Shionogi – RADICAVA US$2.5B Transaction (April 2026)1 Transaction: Shionogi acquired global rights to RADICAVA (IV edaravone) and RADICAVA ORS (oral edaravone) from Tanabe Pharma. Deal value: US$2.5 billion upfront (lump sum), with potential additional royalties on future sales (subject to conditions). Timing: Announced 22 December 2025 and completed in early April 2026 Asset profile: A commercial, revenue-generating ALS therapy franchise with both IV and oral formulations already in market. Strategic rationale: Strengthened Shionogi’s rare disease commercial platform (especially US), adding established programs/teams and readiness to launch additional rare disease treatments. Other Recent ALS Deals Eli Lilly entered neurodegenerative disease collaborations with Alchemab2 (2025; reported up to US$415M) and QurAlis3 (2024; US$45M upfront plus potential milestones). Eli Lilly and Verge Genomics4 entered an ALS discovery collaboration in 2021. Public reports described potential transaction economics of approximately US$694M. Ferrer: Prilenia and Ferrer announced a strategic collaboration and licensing agreement relating to pridopidine in 2025.5 1. Shionogi press release, 22 December 2025; transaction completion announced April 2026. 2. Alchemab Therapeutics press release, 6 May 2025 3. QurAlis press release, 3 June 2024 4. Fierce Biotech, 6 January 2021 5. Prilenia Therapeutics press release, 28 April 2025 2: mTOR pathway-related diseases NUZ-001: Strong portfolio protection 2035 2040 2030 2025 2015 2020 Patent Families for monepantel 1: Human kinase inhibitor 3: Combinatorial treatments 4: API repurposing protection 5: Neurodegenerative diseases What is protected: • Key analogues of monepantel • Optimised dosing, formulation and combo strategies • Monepantel use in neurodegenerative and mTOR-related diseases Protected Jurisdictions: 1. AU, CA, CN, EU, CH, HK, JP, SK, USA 2. AU, CA, CN, EU, CH, HK, JP, SK, USA 3. AU, CA, CN, EU, CH, HK, JP, SK, USA 4. AU, EU, CH, JP, USA 5. AU, USA; Pending: CA, EU, HK, JP 16 Company Presentation April 2026 In addition to patent protection, NUZ-001 has US Orphan Drug Designation (ODD) and European Orphan Medicinal Product Designation (OMPD) providing 7 and 10 years of market exclusivity, respectively. Demonstrating Meaningful Progress Successfully raised $7.1m through a share placement 17 Executed Global License Agreement with Elanco Regimen “I” commenced in the HEALEY ALS Platform Trial Successful manufacture of three registration batches of NUZ-001 Received ~$6m cash rebate from R&D Tax Incentive for FY2025 Promising exploratory top- line results from Phase 1 and OLE study R&D Tax Incentive Advance & Overseas Finding Approval Raised $5.88m through Entitlement Offer to Eligible Shareholders Australian Patent granted for NUZ-001 – Expiry 2041 Established a $20m strategic con note facility with Obsidian Secured registered trademark protection for NEURIZON® Company Presentation April 2026 Strengthened preclinical data and understanding of the MOA of NUZ-001 18 Disciplined Communication During a High-Execution Period Since April 2025, NUZ maintained regular market disclosure across key operational and value- driving milestones. Analysis period from 22 April 2025 through to 20 March 2026 Company Presentation April 2026 95 47 39 47 8 9 A strong cadence of substantive updates reflecting active execution and transparency. SUBSTANTIVE UPDATES BY CATEGORY Across 39 unique trading days Total ASX announcements Substantive market updates¹ Trading days with substantive updates¹ ¹ Excludes procedural filings such as cleansing statements, securities quotation applications and escrow releases. Substantive updates¹ across 39 trading days Clinical & Regulatory Scientific & Preclinical Non-Dilutive Funding Capital Management / Raisings Financial Reporting Corporate Governance This communication cadence reflects active operational execution and a commitment to timely shareholder disclosure. 5 6 10 3 19 What Comes Next in Our Growth Strategy Company Presentation April 2026 Potential Value Outcomes: Our Focus Areas: Ongoing clinical execution Continued data generation Progressing the Regulatory Pathway Further strengthening of scientific insight Partnership expansion and opportunities Clinical de-risking driving higher probability of success High-quality data generating long-term value Sustainable value creation for shareholders Stronger partnerships creating scale and reach Regulatory progress unlocking future milestones and optionality Near-Term Milestones Objectives 20 Q3- Q4 CY 2026 ONGOING EFFORTS ✓ Work to broaden pipeline to other neurodegenerative diseases ✓ Partnership expansion opportunities with patient associations ✓ Targeted engagement with potential strategic partners Company Presentation April 2026 Q2 • Preclinical updates • HEALEY enrollment updates • Liquid Formulation PK Study Initiation • CEO Appointment • VIC and QLD shareholder briefing events • HEALEY tablet supply secured through completion • Liquid Formulation PK Study Completed • EMA Protocol Advice opinion received • PMDA General Consultation completed • HEALEY Trial enrollment complete • Participation at partnering and scientific conferences Preclinical Updates Commercial Supply Agreement with Elanco HEALEY enrollment updates Ethics Approval for Liquid Formulation PK Study EMA Scientific Advice preparation PDMA Regulatory Consultation CNS Partnering, Target ALS, and other major international conferences and partnering events 21 Well-characterised Drug • First-in-class oral small molecule • Validated blood brain barrier penetration • Supportive long-term safety data from Phase 1 and OLE in small population (n=12) Disease-modifying potential • Targets underlying TDP 43 pathology in 97% ALS patients • Preclinical data show multi-pathway protein clearance activity (autophagy and proteasomal system) Phase 2/3 Clinical Trial • Commenced HEALEY ALS Platform Trial • Dosing patients since Feb 2026 • Appears safe and generally well-tolerated with preliminary signs of efficacy in exploratory P1 and OLE studies Current ALS Treatments • High unmet need for disease modifying treatment • Limited efficacy with current options NUZ-001 Opportunity • 15% annual sales growth rate of ALS market, US$1.28B by 2029 • 0.8% annual ALS patient population growth • Potential to address other neurodegenerative diseases Strong Market Readiness • Patent protection in USA and AU out to 2041, with EU and JP pending • EMA Orphan Medicinal Product Designation • FDA Orphan Drug Designation ✓ Company Presentation April 2026 Showing Promising Survival Trends in ALS NUZ-001: Orphan Drug Designated Small Molecule ✓ ✓ ✓ ✓ ✓ Q&A Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com THANK YOU